Latest news with #woundhealing
Zawya
2 days ago
- Business
- Zawya
Sky Medical Technology announces geko device adoption in Dubai hospitals
Dubai, UAE June 3rd 2025: Global medical device manufacturer Sky Medical Technology (Sky), parent company of Firstkind Ltd, today announced Dubai-based Genesis Healthcare, Dubai London Hospital and Mediclinic Parkview Hospital have adopted Sky Medical's innovative geko® device to accelerate chronic wound healing (leg ulcers), prevent and treat lower limb oedema (swelling) and to prevent venous thromboembolism (VTE - blood clots) in medically ill and immobile patients. The size of a small wrist-watch, the geko device is a wearable neuromuscular electrostimulator that is applied to the surface of the skin just below the knee. It delivers a gentle electrical pulse, once per second, to the common peroneal nerve, activating the calf and foot muscle pumps, increasing venous, arterial, and microcirculatory blood flow at a rate equal to 60%1 of walking, replicating the effects of exercise without a patient having to move. Commenting on the adoption of the geko device, Dr Ibrahim Riza, Consultant Vascular and Endovascular Surgeon, said: 'The geko device has been a game-changer in my practice. External compression, multi-layer bandaging, and drugs are the current standard of care for increasing blood circulation, but they do not work for all conditions. External compression and bandaging therapies can be complex to apply and uncomfortable to wear, leading to poor patient compliance, and drugs can carry an unpredictable bleed risk. The geko device overcomes these challenges and is uniquely positioned to address significant unmet needs when drug and current compression devices are impractical or contraindicated. As well as chronic wound healing and post-stroke VTE prevention, the geko device is highly effective in addressing lymphedema and maternity and travel-related oedema.' 'One of its biggest advantages is ease of use. The geko device is lightweight, silent, and completely non-invasive. Patients can wear it while sitting, lying down, and moving around, making it ideal for immobile patients and for those who are active in managing their recovery following surgery. By offering my patients the geko device, I provide them with a safe, comfortable, and effective way to support their vascular health, without the need for drugs or bulky equipment.' Commenting on behalf of Sky Medical Technology, CEO and Founder Bernard Ross: 'I am delighted that Dr Ibrahim Riza and his clinical team are benefiting from the geko device, which provides an effective and non-invasive way to manage vascular health and enhance recovery. We are proud to be partnered with hospitals and clinicians in Dubai who share our vision for advanced therapies that can deliver better patient outcomes and healthcare system savings.' About the geko device The patented geko device is a NICE-approved (MTG19), FDA-cleared, wearable neuromuscular electrostimulor. The size of a wristwatch and worn at the knee, the geko device gently stimulates the common peroneal nerve, activating the calf and foot muscle pumps, resulting in increased blood flow in the deep veins of the calf 2- at a rate equal to 60%1 of walking without a patient having to move. The blood flow volume and velocity increase prevents blood pooling and clotting, treats and prevents trauma-based and post-operative oedema, and in chronic wound care improves microcirculatory blood flow, delivering oxygenated blood to the wound bed to promote wound healing: About Firstkind and Sky Medical Technology Ltd Sky Medical Technology, the parent of Firstkind Ltd, is a UK-based medical devices company. Through its innovative mechanism of neuromuscular electrostimulation, Sky has developed a non-invasive, ground-breaking technology platform, OnPulse®, embedded in its industry-leading brand, the geko device. Sky's products are tailored to different medical application areas, selling through strategic partnerships or distributors in each major clinical area. Clinical areas of focus include life-threatening blood clots, complications related to swelling after surgery, and vascular conditions related to wound healing. The goal in each pathway is to partner with healthcare professionals to improve clinical outcomes and patient care whilst saving health system resources. About the Dubai hospitals Genesis Healthcare excels in advanced diagnostics and personalized care, making it a top choice for comprehensive wellness. Dubai London Hospital is known for its British-standard medical expertise, offering premium care across multiple specialties. Mediclinic Parkview Hospital stands out for its state-of-the-art technology, international medical staff, and patient-centric approach. Together, these hospitals represent the best of Dubai's healthcare sector, blending innovation, quality, and compassionate service to meet diverse patient needs in a world-class medical environment. About Abu Dhabi International Medical Services (ADI) Abu Dhabi International Medical Services (ADI) is a leading healthcare solutions provider in the UAE. As the exclusive distributor of the geko device from Firstkind, ADI brings advanced technology and expert support to enhance patient care across the region. Media contact Jargon Group
Trade Arabia
3 days ago
- Business
- Trade Arabia
Dubai hospitals to use geko device for patients
Dubai-based Genesis Healthcare, Dubai London Hospital and Mediclinic Parkview Hospital have adopted Sky Medical's innovative geko device to accelerate chronic wound healing (leg ulcers), prevent and treat lower limb oedema (swelling) and to prevent venous thromboembolism (VTE - blood clots) in medically ill and immobile patients. The size of a small wrist-watch, the geko device is a wearable neuromuscular electrostimulator that is applied to the surface of the skin just below the knee. It delivers a gentle electrical pulse, once per second, to the common peroneal nerve, activating the calf and foot muscle pumps, increasing venous, arterial, and microcirculatory blood flow at a rate equal to 60% of walking, replicating the effects of exercise without a patient having to move, said global medical device manufacturer Sky Medical Technology. Dr Ibrahim Riza, Consultant Vascular and Endovascular Surgeon, said: 'The geko device has been a game-changer in my practice. External compression, multi-layer bandaging, and drugs are the current standard of care for increasing blood circulation, but they do not work for all conditions. External compression and bandaging therapies can be complex to apply and uncomfortable to wear, leading to poor patient compliance, and drugs can carry an unpredictable bleed risk. The geko device overcomes these challenges and is uniquely positioned to address significant unmet needs when drug and current compression devices are impractical or contraindicated. As well as chronic wound healing and post-stroke VTE prevention, the geko device is highly effective in addressing lymphedema and maternity and travel-related oedema. 'One of its biggest advantages is ease of use. The geko device is lightweight, silent, and completely non-invasive. Patients can wear it while sitting, lying down, and moving around, making it ideal for immobile patients and for those who are active in managing their recovery following surgery. By offering my patients the geko device, I provide them with a safe, comfortable, and effective way to support their vascular health, without the need for drugs or bulky equipment.' Sky Medical Technology CEO and Founder Bernard Ross: 'I am delighted that Dr Ibrahim Riza and his clinical team are benefiting from the geko device, which provides an effective and non-invasive way to manage vascular health and enhance recovery. We are proud to be partnered with hospitals and clinicians in Dubai who share our vision for advanced therapies that can deliver better patient outcomes and healthcare system savings.'
Yahoo
28-05-2025
- Business
- Yahoo
DEBRA Research and Dermaliq Enter into a Strategic Collaboration to Advance Cutaneous Drug Delivery for Epidermolysis Bullosa
Initial programs will focus on developing innovative topical treatments and drug therapies for wound healing and itch relief, plus prophylactic therapies for people with Epidermolysis Bullosa. Dermaliq's proprietary hyliQ® technology platform enables touchless delivery of novel drug therapies to fragile, sensitive or disease-affected skin. MUNICH and WILMINGTON, Del., May 28, 2025 (GLOBE NEWSWIRE) -- DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for those affected by Epidermolysis Bullosa (EB), and Dermaliq Therapeutics, Inc., a clinical-stage dermatology innovator company developing next-generation topical therapies, today announced a strategic, non-exclusive collaboration to advance cutaneous drug delivery into the skin for EB. Initially, the partners will focus on improving wound-healing and anti-itch therapies, plus developing prophylactic therapies for people suffering from EB. As part of the agreement, DEBRA Research has also made a strategic investment in Dermaliq. EB is a group of rare and painful genetic skin disorders characterized by extremely fragile skin, leading to blisters and wounds from even minor friction or trauma. EB significantly affects the daily lives of people living with the condition and is associated with substantial morbidity and mortality over time due to chronic wounds, infections, and complications involving internal organs. It is caused by mutations in one or more genes that encode proteins responsible for maintaining the structural integrity of the skin. While there is currently no cure, novel treatments are being developed to manage symptoms, reduce pain, and improve quality of life. Dermaliq is set to transform therapeutic strategies for skin and wound management in EB. Leveraging its proprietary hyliQ® technology, the company enables targeted delivery of active compounds into the skin without mechanical interference to fragile or wounded tissue. Applied touchless, hyliQ® is designed specifically for conditions like EB, where the skin is exceptionally delicate and prone to blistering or damage from even minimal friction. This innovative approach offers critical therapeutic benefits for patients by delivering effective treatments while preserving the integrity of compromised skin. 'This partnership aligns closely with our mission to accelerate the development of effective, high-impact therapies for people living with EB,' said Dr Christoph Coch MD, Managing Director at DEBRA Research. 'Dermaliq's unique technology platform and clinical pipeline offer a promising approach to overcome the limitations of existing topical treatments, particularly for application on the damaged and fragile skin characteristic of EB. We believe this collaboration will play a pivotal role in advancing transformative therapies and improving both medical outcomes and quality of life for those affected by this devastating condition.' 'We are excited to join forces with DEBRA Research to bring our technology to an area of urgent and unmet medical need,' said Frank Löscher, PhD, CEO of Dermaliq. 'This partnership underscores our shared commitment to addressing the urgent needs of people living with this debilitating disorder. With its unique features and exceptional safety profile, hyliQ® is ideally suited for the touchless topical treatment of disease-affected and damaged skin. We look forward to the impact this collaboration can bring to the EB community and beyond.' About DEBRA Research DEBRA Research is a non-profit organization dedicated to advancing treatments and cures for EB, a rare and life-limiting genetic condition. As the research arm of DEBRA Austria – a patient organization established in 1995 to support individuals living with EB – DEBRA Research collaborates globally with academia, biotech, pharma, patient organizations, and regulatory bodies to drive innovation. DEBRA Research focuses on translational research and clinical development to address the unmet needs of people living with EB. Its goal is to accelerate the discovery and development of treatments improving quality of life, while striving for a future where EB is curable – a 'world without EB.' For more information, please visit and follow us on LinkedIn. About Dermaliq Therapeutics Dermaliq Therapeutics, Inc. is uniquely positioned to revolutionize topical dermatology. With our proprietary hyliQ® technology platform, we are breaking through traditional delivery barriers, enabling for the first time the targeted absorption into skin structures with unmatched bioavailability and cutaneous tolerability. This breakthrough paves the way for first-in-class and best-in-class topical treatments with broad application across dermatology and rare disease indications, offering substantial opportunities for long-term growth and value creation. Dermaliq's pipeline includes clinical stage assets in androgenetic alopecia, alopecia areata and wound healing. For more information, visit Contacts DEBRA Research GmbHDr Christoph Coch, Managing Director Email: info@ Dermaliq Therapeutics, Frank Löscher, CEOEmail: aga@ Media Inquiries MC ServicesDr Cora Kaiser, Dr Johanna KoblerPhone: +49 89 210 2280Email: debra-research@ in to access your portfolio
Yahoo
11-05-2025
- Health
- Yahoo
One early warning sign in your body could be an indicator of type 2 diabetes
Type 2 diabetes occurs when the body doesn't produce enough insulin or the body's cells don't properly react to insulin, resulting in high blood sugar levels. This excess glucose can harm blood vessels, raising the risk of artery damage and strokes. One early sign of type 2 diabetes is if cuts or wounds take longer than usual to heal. According to "High levels of blood glucose [sugar] caused by diabetes can, over time, affect the nerves (neuropathy) and lead to poor blood circulation, making it hard for blood - needed for skin repair - to reach areas of the body affected by sores or wounds." This can result in wounds staying open and not healing as they should, increasing the chance of additional complications. Of particular concern are slow-healing foot wounds in diabetic individuals, which could lead to a higher risk of amputation if not treated correctly, as reported by Surrey Live. READ MORE: DWP confirms 150,000 claimants will see cuts in Carer's Allowance and Universal Credit READ MORE: Weekend warning as two key Stoke-on-Trent roads to shut The NHS lists symptoms of type 2 diabetes and advises those with the condition to check their feet every day and report any damage to their healthcare provider. Managing blood sugar levels is vital in reducing the risk of slow-healing injuries and staving off type 2 diabetes. Essential to maintaining a balanced glucose level is an appropriate diet, notes Harvard Health, recommending a blend of fruits, veggies, whole grains, pulses, and low-fat dairy options, reports Surrey Live. Harvard Health has noted: "Vegetables, fruits, and whole grains provide more nutrition per calorie than refined carbohydrates and tend to be rich in fibre." It further states: "Your body digests high-fibre foods more slowly - which means a more moderate rise in blood sugar." While experts suggest moderating the intake of highly refined carbs like white bread and sugary snacks and drinks, Diabetes UK recognises that dietary needs can vary from person to person. Nevertheless, the charity encourages making wholesome choices routinely, indulging in treats sparingly and in small amounts. Additionally, it cautions against products marketed as 'diabetic' or 'suitable for diabetics', and advises reducing the consumption of red and processed meats as well as overly refined carbohydrates such as white bread.
Health Line
10-05-2025
- Health
- Health Line
What Do Platelets Do?
Platelets are small types of blood cells that prevent excessive bleeding. It's possible to develop low or high platelet counts related to a number of health conditions. Platelets are one of the main types of blood cells in your body, along with red blood cells and white blood cells. Also known as thrombocytes, platelets are responsible for helping your blood clot to prevent excess bleeding and to promote wound-healing. Having a normal number of platelets in your bloodstream is important for these cells to perform their functions. However, problems can arise when your body makes too few or too many platelets. In other cases, your platelets don't function at all like they should. Learn more about blood platelets, including how they work in your body, as well as related health conditions and possible symptoms to discuss with a doctor. What is the function of platelets? Platelets help to form plugs called blood clots. This is important to slow down or prevent excess bleeding in the case of external or internal wounds. Without platelets, it's possible to experience internal or spontaneous bleeding, which can be fatal. When you get injured, platelets adhere to your blood vessel walls to help prevent further bleeding from occurring. Platelet structure and anatomy Platelets are made in your bone marrow. These are the smallest types of blood cells, with each one living approximately 7 to 10 days. Unlike red and white blood cells, platelets do not contain nuclei. During the early stages of their formation, they are megakaryocytes, or large bone marrow cells. Each megakaryocyte contains an organelle that eventually becomes a smaller disc-sized platelet that can move easily through your bloodstream to help form clots and heal wounds. Any platelet that is larger than its typical post-megakaryocyte size of 2 μm (microns) in diameter could indicate an underlying condition, such as a genetic disorder or an autoimmune disease. Your spleen also plays a role in filtering and storing platelets. What is a normal platelet count? A normal platelet count is considered anywhere between 150,000 and 400,000 platelets per microliter. Any result above 450,000 platelets per microliter is considered high, while any level below 150,000 is considered a low platelet count. A health care professional can make this determination based on blood test results. Depending on their findings, they may then order additional labs and tests, including a possible abdominal ultrasound. What medical conditions affect platelets? A low platelet count (thrombocytopenia) and a high platelet count (thrombocythemia or thrombocytosis) can both be serious, and possibly fatal when left untreated. Each one can be associated with certain medical conditions. Medical conditions that affect a low platelet count Thrombocytopenia can prevent your blood from clotting like it is supposed to, and may lead to excess bleeding. The most common causes include: Primary immune thrombocytopenia (ITP): Also called idiopathic ITP, this is a type of autoimmune condition in which your immune system attacks healthy platelets and destroys them. It may be treated with immunosuppressants or other medications. Secondary ITP: This refers to low platelets caused by an existing autoimmune disease, such as rheumatoid arthritis (RA) and lupus. Medications: These include acetaminophen (Tylenol), ibuprofen (Advil), and heparin. A doctor may have you discontinue the medication they suspect is causing low platelets. Infections: Malaria, viral infections like hepatitis C and HIV, and sepsis may all decrease blood platelet levels. Genetics: Some forms of thrombocytopenia may develop in children, but rarely do so in adults. Examples include Von Willebrand disease type 2 and Fanconi syndrome. Nutritional deficiencies: Vitamin B12, folate, and copper deficiencies are all linked to low platelet counts. Aplastic anemia: Also called bone marrow failure, aplastic anemia occurs when your bone marrow can no longer produce new blood cells, including platelets. A blood transfusion or bone marrow transplant may be required. Spleen issues: While the spleen is responsible for storing platelets, it can sometimes store too many of them, leading to a lower platelet count in your bloodstream. This may be treated with spleen removal (splenectomy), which is also a second-line treatment for primary ITP. Medical conditions that affect a high platelet count A high platelet count can lead to the formation of blood clots in your blood vessels. These can stop the normal flow of blood and can lead to potentially life-threatening complications like heart attack or stroke. Secondary thrombocytosis describes a high platelet count caused by certain medical conditions, such as: Infections: These include chronic infections like tuberculosis, as well as acute bacterial or viral infections. Treating the underlying infection may help normalize platelet counts. Medications: Possibilities include certain antibiotics and cancer drugs. Discontinuing the suspected medication can help address high platelet counts. Inflammatory diseases: RA, sarcoidosis, and inflammatory bowel disease (IBD) are all examples. Treating the underlying condition will help normalize platelet levels. Iron deficiency anemia: Restoring iron levels is a first step in addressing this condition, and it may also help lower high platelet levels. Cancer: Thrombocytosis is associated with several cancers, including those in the blood, colon, and abdominal area. If you are at risk of blood clots, a doctor might recommend antiplatelet medications, such as anagrelide (Agrylin) to help decrease your platelets. What are the symptoms of conditions that affect platelets? The symptoms associated with a platelet-related health condition can depend on whether you have low or high platelet counts. Possible signs and symptoms associated with a low platelet count include: easy bleeding from your gums, nose, or small injuries easy bruising blood in your urine or stool vomiting blood small, flat spots underneath your skin that may be red, brown, or purple, depending on skin tone (petechiae) spots from bleeding in your skin (purpura) heavy menstruation extreme fatigue weakness splenic or liver enlargement A high platelet count can also sometimes cause excess blood clotting, as well as liver or splenic enlargement. Other possible signs and symptoms may include: headaches unexplained tiredness dizziness extreme weakness chest pain heart palpitations swelling or pain in your legs breathing difficulties vision changes slurred speech Frequently asked questions about platelets How do doctors check your platelet count? A platelet count is measured as part of a complete blood count (CBC), which also measures your red and white blood cell counts. Sometimes, in addition to the number of cells, a doctor will also order additional lab testing to get a better look at the size and shape of your platelets to help make a more accurate diagnosis. This is called a peripheral blood smear, and is done with a microscopic examination. A platelet count is measured as part of a complete blood count (CBC), which also measures your red and white blood cell counts. Sometimes, in addition to the number of cells, a doctor will also order additional lab testing to get a better look at the size and shape of your platelets to help make a more accurate diagnosis. This is called a peripheral blood smear, and is done with a microscopic examination. What level of platelets is dangerous? A platelet count of less than 20,000 per microliter is considered severely low, and potentially dangerous. However, any platelet count lower than 150,000 or higher than 450,000 per microliter may be considered serious. A platelet count of less than 20,000 per microliter is considered severely low, and potentially dangerous. However, any platelet count lower than 150,000 or higher than 450,000 per microliter may be considered serious. How can you increase platelets? A low platelet count is typically treated with medications. For example, primary ITP may be treated with immunosuppressants that prevent your immune system from attacking and destroying platelets in the bone marrow. Regardless of the exact cause of thrombocytopenia, any significant bleeding that occurs with this condition will likely be treated with a blood transfusion. You may also consider avoiding certain lifestyle habits that might worsen thrombocytopenia, such as smoking and drinking alcohol. A low platelet count is typically treated with medications. For example, primary ITP may be treated with immunosuppressants that prevent your immune system from attacking and destroying platelets in the bone marrow. Regardless of the exact cause of thrombocytopenia, any significant bleeding that occurs with this condition will likely be treated with a blood transfusion. You may also consider avoiding certain lifestyle habits that might worsen thrombocytopenia, such as smoking and drinking alcohol. What is platelet-rich plasma (PRP)? Platelet-rich plasma (PRP) is a type of injectable treatment touted for a variety of purposes, including injuries and dermatological conditions. It's made from your own blood, where the process of centrifugation increase the platelet count up to 5 to 10 times. PRP was previously used for platelet disorders, such as thrombocytopenia. With that said, PRP is primarily coveted for its proteins as a therapeutic procedure, and not as a first-line treatment for low platelet counts. PRP is different from a blood transfusion. Platelet-rich plasma (PRP) is a type of injectable treatment touted for a variety of purposes, including injuries and dermatological conditions. It's made from your own blood, where the process of centrifugation increase the platelet count up to 5 to 10 times. PRP was previously used for platelet disorders, such as thrombocytopenia. With that said, PRP is primarily coveted for its proteins as a therapeutic procedure, and not as a first-line treatment for low platelet counts. PRP is different from a blood transfusion. Takeaway Along with red and white blood cells, platelets make up an important part of your blood. These small cells are the byproducts of large bone marrow cells, and can help stop bleeding from minor injuries. Due to their role in forming blood clots and preventing internal bleeding, it's important that you have the right number of platelets. An abnormally low or high platelet count can develop due to inherited or acquired medical conditions, as well as certain medications. If a doctor suspects a platelet disorder, they will run a CBC test to determine your current platelet counts. The result will help determine any further diagnostic testing and treatment.
